PMID- 24810970
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20151119
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 49
IP  - 5
DP  - 2014 May
TI  - Minimal clinically important difference in myasthenia gravis: outcomes from a 
      randomized trial.
PG  - 661-5
LID - 10.1002/mus.23988 [doi]
AB  - INTRODUCTION: The minimal clinically important difference (MCID) is the smallest 
      outcome change that has clinical significance. Its use has not been established 
      in the study of myasthenia gravis (MG). METHODS: Patients from a published 
      intravenous immunoglobulin (IVIg) vs. placebo study were studied. One 
      anchor-based and 3 distribution-based techniques were used to identify 
      quantitative myasthenia gravis score (QMGS), repetitive nerve stimulation (RNS), 
      and single-fiber electromyography (SFEMG) MCID cut-offs. Patients with a 
      change-score exceeding MCID cut-offs were compared. RESULTS: MCID cut-offs were 
      below a QMGS change of 3.0. Anchor-based and 1 x SEM cut-offs showed 58.3% vs. 
      30.7% responders (P = 0.017), (1/2) SD 54.2% vs. 19.2% responders (P = 0.018), and 
      effect size 0.519 vs. 0.164 (P = 0.011) in IVIg vs. placebo. Anchor-based 
      (P = 0.73) and effect-size (P = 0.41) MCID cut-offs did not show a difference 
      between IVIg and placebo. MCID methods did not produce meaningful RNS cut-offs. 
      CONCLUSIONS: QMGS MCID values provide clinically relevant information and are 
      recommended in MG trials. MCID analysis shows that improvement in MG patients 
      treated with IVIg reflects clinically meaningful changes.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
FAU - Katzberg, Hans D
AU  - Katzberg HD
AD  - University Health Network, Division of Neurology, Toronto General Hospital, 200 
      Elizabeth Street, 5ES-306, Toronto, Ontario, M5G 2C4, Canada.
FAU - Barnett, Carolina
AU  - Barnett C
FAU - Merkies, Ingemar S J
AU  - Merkies IS
FAU - Bril, Vera
AU  - Bril V
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140204
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Clinical Trials as Topic/methods
MH  - Electromyography
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/diagnosis/*drug therapy
MH  - ROC Curve
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
OTO - NOTNLM
OT  - MCID
OT  - QMGS
OT  - myasthenia gravis
OT  - neuromuscular junction
OT  - outcomes
EDAT- 2014/05/09 06:00
MHDA- 2014/05/28 06:00
CRDT- 2014/05/10 06:00
PHST- 2013/08/01 00:00 [accepted]
PHST- 2014/05/10 06:00 [entrez]
PHST- 2014/05/09 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 10.1002/mus.23988 [doi]
PST - ppublish
SO  - Muscle Nerve. 2014 May;49(5):661-5. doi: 10.1002/mus.23988. Epub 2014 Feb 4.